Fabrice Andre, Ahmed Khalil, Khemaies Slimane, Christophe Massard, Marie Christine Mathieu, Stéphane Vignot, Hazem Assi, Suzette Delaloge, Marc Spielmann
PURPOSE: We have evaluated whether the mitotic index could predict the benefit of adjuvant anthracycline-based chemotherapy in patients with early breast cancer who are eligible for adjuvant chemotherapy according to Saint Gallen guidelines. PATIENTS AND METHODS: A total of 937 patients from a single institution were included in two randomized trials that compared adjuvant anthracycline-based chemotherapy with no chemotherapy. These patients account for 83% of the overall population included in these trials...
May 1, 2005: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology